Daiichi Sankyo extends the PREFER in AF patient registry to provide additional insights into the long-term management of

Daiichi Sankyo's European base is located in Munich and has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany. For more information, please visit: http://www.daiichi-sankyo.eu.

Forward-looking statements

This press release contains forward-looking statements and information about future developments in the sector,and the legal and business conditions of Daiichi Sankyo Europe GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. Daiichi Sankyo Europe GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References:

        
        1) Iqbal, M. B., Taneja, A. K., Lip, G. Y. H. & Flather, M. Recent
          developments in atrial fibrillation. BMJ. 2005;330:238-43.
        2) Camm, A. et al. Guidelines for the management of atrial fibrillation: the
          Task Force for the Management of Atrial Fibrillation of the European Society of
          Cardiology (ESC). European Heart Journal. 2010;31:2369-429.
        3) Kirchhof P, et al. Management of atrial fibrillation in seven European
          countries after the publication of the 2010 ESC Guidelines on atrial fibrillation:
          primary results of the PREvention oF thromboembolic events - European Registry in
          Atrial Fibrillation (PREFER in AF). Europace 2013. doi: 10.1093/europace/eut263.
        4) Jones, M. et al. Evaluation of the pattern of treatment, level of
          anticoagulation control, and outcome of treatment with warfarin in patients with
          non-valvar atrial fibrillation: a record linkage study in a large British population.
          Heart. 2005:91:472-7.
        5) National Institute for Health and Care Excellence. Atrial fibrillation: the
          management of atrial fibrillation. Clinical guideline: Methods, evidence and
          recommendations. January 2014. Available at:
          http://www.nice.org.uk/nicemedia/live/13... [Last accessed: March
          2014]
        6) Lin, H., Wolf, P. A., Kelly-Hayes, M. & Benjamin, E. J. Stroke Severity in
          Atrial Fibrillation. Stroke. 1996;27:1760-1764.
        7) Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in
          five European countries: results from the Euro Heart Survey on atrial fibrillation.
          Europace. 2008;10(4):403-11.
        8) Bueller, H et al. Edoxaban versus Warfarin for the Treatment of Symptomatic
          Venous Thromboembolism. N Engl J Med 2013;369:1406-1415.
        9) Giugliano, R et al. Edoxaban versus Warfarin in Patients with Atrial
          Fibrillation. N Engl J Med 2013;369:2093-2104.
          10) Ogata, K et al. Clinical Safety, Tolerability, Pharmacokinetics, and
          Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. J
          Clin Pharmacol 2010;50:743-753.

        
        For more information, please contact:

        Daria Munsel
        Daiichi Sankyo Europe GmbH
        Tel: +49-(89)-7808728 (Office)